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Multiple Biomarker Prediction of Type 2
Diabetes
T
ype 2 diabetes is predictable and
preventable.Obesity,familialdiabe-
tes, and higher-than-normal blood
glucose levels are well-known risk factors
for development of type 2 diabetes by
middle age; recent prediction models
have incorporated these with other
readily measurable features of metabolic
syndrome (elevated blood pressure, low
HDL cholesterol, and elevated triglycer-
ides) to generate validated prediction
rules (1–3). In clinical care, a patient of
European descent with a family history of
diabetes, obesity, and features of meta-
bolic syndrome is at 25-fold increased
risk to develop type 2 diabetes in the next
few years relative to a patient without
these characteristics (4). With regard to
the public health of the population, these
characteristics very reliably discriminate
groupsatrelativelyhighriskfromthoseat
low risk (3). Once high-risk patients are
identiﬁed, those adherent to a program of
30 min of moderate physical activity
per day and weight loss of 5–10% of ini-
tial body weight can expect that risk for
type 2 diabetes will be reduced by at least
50% relative to patients not following a
therapeutic lifestyle program (5).
The relatively simple recognition of
pre-diabetes and prevention of its trans-
formationtodiabetesmaybewell-known
to the readers of Diabetes Care. However,
some will raise concerns regarding prac-
tical problems obtaining fasting or oral
glucose tolerance blood tests, the high
intraindividual variability in blood glu-
cose levels (6), the fact that fewer than
20% of white people with obesity will
progress to diabetes over subsequent
years (7), and the fact that the genetics
that presumably underlie familial type 2
diabetes do not seem to add much to its
predictability (8). Perhaps less well-
knownistheexpandingunderstandingof
pathophysiological axes beyond the clas-
sic triumvirate of -cell, skeletal muscle,
and liver (9) that contribute to the pre-
diabeticstate.Abnormaladipocytesignal-
ing (10), subclinical inﬂammation (11),
endothelial dysfunction (12), iron over-
load (13), incretin system abnormalities
(14), and variation in the Circadian sys-
tem (15,16) all appear to add substantial
complexity to type 2 diabetes–risk phys-
iology, offering potential targets for
alternate or improved type 2 diabetes
screening approaches.
In this issue of Diabetes Care, Kolberg
et al. (17) used the experience of the In-
ter99 cohort to develop a model for as-
sessing the 5-year risk of incident type 2
diabetesbasedonapanelof64circulating
candidate biomarkers. In a nested case-
control design, they selected from a pop-
ulation-based sample of 6,600 Danes
160individualswhodevelopedtype2di-
abetes and 472 who did not. They mea-
sured several clinical variables, collected
fastingserum,andmeasuredmanycandi-
date biomarkers from multiple diabetes-
associated pathways. Their assay system
employed an ultrasensitive immunoassay
microsample molecular counting tech-
nology. The biomarkers were initially se-
lected based on a thorough search of the
current diabetes biomarker literature,
narrowed based on the availability of as-
say reagents that could be incorporated
with high quality into the assay system,
and then further selected using statistical
modeling.
Theirbiomarkerselectionandmod-
eling method was thorough and ex-
haustive. They used a wide variety of
approaches: biomarker selection based
on biologically sensible hand-ﬁt models
or highly data-driven trial-and-error
models. The modeling led ultimately to
six biomarkers that gave a Diabetes Risk
Score. The approach involved a high de-
gree of multiple hypothesis testing. They
appropriately controlled the type 1 error
rate through permutation estimations of
minimum P values observed for a ran-
domly distributed outcome given the
number of tests performed. Although
they did not test the Diabetes Risk Score
in an entirely independent sample, they
provided good estimates of both the error
around the model ﬁt and discrimination
using split-sample and bootstrap tech-
niques.Giventhethoroughnessoftheap-
proach, there is no doubt that Kolberg et
al. present the most robust multimarker
prediction model possible given the bio-
markers initially measured and the
source population. The authors appro-
priately note that the approach may
only apply to white Northern Europe-
ans enrolled in a lifestyle intervention
trial. Whether the model would pro-
duce the same biomarkers or discrimi-
nate well in race/ethnicity populations
that are differentially affected by diabe-
tes was not addressed.
The best predicting model included
adiponectin, C-reactive protein (CRP),
ferritin,interleukin-2receptorA(IL2RA),
glucose,andinsulin,withareaunderthea
receiver operator characteristic curve
(AROC)of0.76–0.78,indicatingthatthe
model would correctly pick the higher-
risk subject from a pair of at-risk subjects
76–78% of the time. This model had bet-
ter discrimination than models including
the single variables A1C, fasting plasma
glucose (FPG), fasting serum insulin,
BMI, or sex-adjusted waist circumfer-
ence;amodelusingFPGandinsulin(that
is, adding adiponectin, CRP, ferritin, and
IL2RA to glucose and insulin; AROC 
75%)thatincreasedtheAROCbyabout
1–3%; or a model including age, BMI,
waistcircumference,andfamilyhistoryof
type 2 diabetes in ﬁrst-degree relatives
(AROC  70%). Combining age, BMI,
waistcircumference,andfamilyhistoryof
diabetes with the Diabetes Risk Score
(that is, adding novel biomarkers to obe-
sity, family history, FPG, and insulin) re-
sulted in an AROC of 79%, which
increased the AROC by 1%. Subjects in
the highest 10% of the Diabetes Risk
Score distribution had a 5-year risk of di-
abetes 3.5 times higher than the popu-
lation’s average risk, which was higher
than the relative risk associated with im-
paired fasting glucose (IFG) (FPG 100
mg/dl, risk relative to normal glucose tol-
erance  1.4). IFG represented 56% of
the sample; not reported is the risk asso-
ciated with the top 10% of the FPG dis-
tribution relative to the population’s
average risk, which would be a fairer way
to make this comparison.
There a couple of ways to view the
meaningofthedatainthisarticle,includ-
ing the ability of biomarkers to discrimi-
nate future disease and the ability of
biomarkers to reveal pathophysiology.
The authors focus on the former, but the
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approach is found. Here, they show that
in addition to levels of glucose and insu-
lin, markers of inﬂammation (CRP and
IL2RA) and adipocyte signaling (adi-
ponectin) are also independently associ-
ated with type 2 diabetes risk. Whether
levels of ferritin reﬂect inﬂammation or
iron storage physiology cannot be re-
solved by the data. By and large, diabetes
biomarkerliteraturehasfocusedonsingle
markers of physiological axes, although
some studies have attempted multima-
rker analyses of adipose tissue signaling,
inﬂammation, or endothelial dysfunction
(12,18,19).Kolbergetal.exhaustivelyex-
amined biomarkers from many different
axes to arrive at the ﬁnal set. In the online
appendix, they point out that although
the biomarker selection process may not
have identiﬁed the best possible model, it
identiﬁed a good model, and that there
may have been other combinations of
markerswithequalperformance.Theydo
not present the results of every model;
this may explain why levels of plasmino-
gen activator inhibitor 1, von Willebrand
factor, interleukin-6, or sex hormone–
bindingglobulin,showninotherdatasets
to be independently associated with type
2 diabetes risk (18,20,21), were mea-
sured but not found to be in the ﬁnal
Diabetes Risk Score. Multimarker ap-
proaches have likewise been revealing
with regard to the complex pathophysiol-
ogy underlying risk of other cardiometa-
bolic disorders, including hypertension,
metabolic syndrome, and cardiovascular
disease (22–25). The present report is the
ﬁrst such effort to create a multimarker
“map” for pre-diabetes physiology. The
results are consistent with the notion that
the physiology underlying development
of type 2 diabetes involves multiple sys-
tems beyond the classic triumvirate of
liver, muscle, and pancreas.
Kolbergetal.,however,focusprimar-
ily on the ability of their Diabetes Risk
Score to discriminate future diabetes. The
value of the score for this use is not clear.
First,themarginaldiscriminatoryvalueof
the novel biomarkers seems quite small
after considering the classic diabetes risk
factors. Next, the proposed Diabetes Risk
Score is now being marketed by Tethys
Bioscience as the “PreDx Diabetes Risk
Test,” which is ﬁne but warrants extra
scrutiny with respect to the new technol-
ogy’s real practical clinical value. The test
requiresa10-hfastingbloodsample.One
imagines that in most routine clinical
practice where fasting blood samples are
taken, a lipid panel is also measured as
part of recommended adult risk factor
screening. One also imagines that if pa-
tients present for fasting blood testing,
they also will be weighed and have their
blood pressure measured. Family history
of diabetes may or may not be assessed,
but if the focus of the exam includes dia-
betes risk screening, then familial diabe-
tes is important to ascertain.
Thus, the key question that is not ad-
dressed by Kolberg et al. is what the mar-
ginal discriminatory capacity of the
Diabetes Risk Score is after considering
fasting glucose and triglycerides, HDL
cholesterol, BMI, blood pressure, and
familyhistoryofdiabetes.Or,putanother
way, it is hard to imagine a situation
where one would measure the “PreDx Di-
abetesRiskTest”butnotfastinglipidsand
anthropometrics. That the Diabetes Risk
Score can be used to generate a continu-
ousestimateofriskisnotauniqueadvan-
tage because other metabolic syndrome
characteristicscanbehandledinthesame
manner (3). Further, whether generation
of a Diabetes Risk Score would be useful
clinically is uncertain. As the authors
pointout,itisunclearthatthesehaveever
been widely adopted by physicians in
practice. A distinct advantage of the met-
abolic syndrome concept, as opposed to
sophisticated biomarker measurement or
modeling, is that metabolic syndrome
offers instant pattern recognition of pa-
tients likely to be at elevated risk for fu-
ture type 2 diabetes. It is not clear that we
need more than a few simple routine clin-
ical measures to identify diabetes risk.
The real challenge is not the need for new
ways to identify pre-diabetes. The chal-
lenge is to ﬁnd better approaches to help
at-risk patients to change their lifestyle
and lose weight because we know for cer-
tain that these changes are powerful
meanstopreventthedevelopmentoftype
2 diabetes.
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